The S 2 -binding substituent, on the other hand, can occupy the S 2 site either covalently or noncovalently
So, I dont think it going to matter that much
Full disclosure, because it colors all of this: Im on Zepbound, Lillys tirzepatide, so I have skin in this as a patient, and I bought Eli Lilly stock about a year ago, partly because I believed exactly the story this post tells
However, while clinical trial results have been promising for PD, they have been less favorable in AD
These access steps ensure products are used safely and appropriately under professional supervision, in line with this brand's supply policy requirements
It means the progress record should include the dose timeline so a clinician can see what happened when